Novo Nordisk on Monday released results from a clinical trial of its blockbuster semaglutide weight-loss drug Wegovy in children.
The pharmaceutical giant touted a reduction in body mass index (BMI) in children ages 6-12 — but the children who took the drug grew more slowly than those who didn’t, The Wall Street Journal reported.
BMI is a measure of body size relative to age and sex, not a direct measure of health. Children who took the drug grew an average of 1.3 inches less than those who did not. Children in that age group typically grow 4-5 inches in two years.
Reduced height is “exactly the signal that should make us pause,” Houman David Hemmati, M.D., Ph.D., posted on X. “Short-term BMI reduction is real. So are the unknowns.”
Children in both the placebo group and the group that received the drug experienced adverse events — 96% in the semaglutide group and 93% in the placebo group.
In the drug group, 70% of the children experienced vomiting compared with 29% in the placebo group. The gastrointestinal side effects were reportedly short-lived and moderate.
“Even so, a young child who vomits often needs close attention to hydration, nutrition, and growth,” Billie Burry, Ph.D., nurse practitioner and educator at Wilkes University in Pennsylvania, told The Defender.
Novo Nordisk published the detailed results in The New England Journal of Medicine this week and presented them at an obesity conference. At the same conference, Eli Lilly announced that its tirzepatide drug Zepbound was effective for adolescent weight loss.
Semaglutide and tirzepatide are both classified as GLP-1 agonist weight-loss drugs.
GLP-1 drugs aren’t currently approved in the U.S. for use for weight loss in children younger than 12.